アルフレッサ HD and 3 other companies executed a stock subscription agreement to subscribe for the common shares of アルフェナックス バイオロジクス. After payment is completed, the 4 companies will establish a joint venture and construct a manufacturing facility in Akita Prefecture, targeting the start of commercial production by fiscal 2031.
アルフレッサ ホールディングス株式会社, Mycenax Biotech Inc., Kidswell Bio Corporation and Chiome Bioscience Inc. executed a stock subscription agreement under which the 4 companies will subscribe for the common shares issued by アルフェナックス バイオロジクス株式会社. The 4 companies plan to establish a joint venture after the subscription, with their ownership interests to be finalized upon completion of payment. アルフェナックス バイオロジクス is a wholly owned subsidiary of アルフレッサ ホールディングス and operates a biopharmaceutical CDMO business and distribution business.
The joint venture's site will be located on the premises of アルフレッサ ファインケミカル株式会社 in Akita, Akita Prefecture, and site preparation is under way for the construction of a manufacturing facility. The new facility is intended to establish an integrated production system covering drug substance manufacturing through finished drug product manufacturing, while strengthening the business foundation by combining the expertise of the companies.